Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense
Trial details
- Registry ID
- NCT06993610
- Phase
- Phase 2
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Tibulizumab Skin Healing and Inflammation Evaluation for Lasting DefenseNCT06993610 | Zura Bio Inc | Phase 2 | Active not recruiting | 2026-09-18Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |